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Abstract
Neurodegenerative diseases comprise a group of chronic and irreversible condi-
tions characterized by the progressive degeneration of the structure and function
of the central nervous system. The detection and classification of patients accord-
ing to the underlying disease are crucial for developing oriented treatments and
enriching prognosis. In this context, Magnetic resonance imaging (MRI) data can
provide meaningful insights into neurodegeneration by detecting the physiological
manifestations in the brain caused by the disease processes. One field of extensive
clinical use of MRI is the accurate and automated classification of neurodegener-
ative disorders. Most studies distinguish patients from healthy subjects or stages
within the same disease. Such distinction does not mirror clinical practice, as a
patient may not show all symptoms, especially if the disease is in an early stage,
or show, due to comorbidities, other symptoms as well. Likewise, automated
classifiers are partly suited for medical diagnosis since they cannot produce prob-
abilistic predictions nor account for uncertainty. Also, existent studies ignore the
spatial heterogeneity of the brain alterations caused by neurodegenerative pro-
cesses. The spatial configuration of the neuronal loss is a characteristic hallmark
for each disorder. To fill these gaps, this thesis aims to develop a classification
technique that incorporates uncertainty and spatial information for distinguishing
four neurodegenerative diseases, Alzheimer’s disease, Mild cognitive impairment,
Parkinson’s disease and Multiple Sclerosis, and healthy subjects. This technique
will produce automated, contingent, and accurate predictions to support clinical
diagnosis.
To quantify prediction uncertainty and improve classification accuracy, this study
introduces a Bayesian neural network with a spatially informed input. A con-
volutional neural network (CNN) is developed to identify a neurodegenerative
condition based on T1−weighted MRI scans from patients and healthy controls.
Bayesian inference is incorporated into the CNN to measure uncertainty and pro-
duce probabilistic predictions. Also, a spatially informed MRI scan is added to
the CNN to improve feature detection and classification accuracy.
The Spatially informed Bayesian Neural Network (SBNN) proposed in this work
demonstrates that classification accuracy can be increased up to 25% by includ-
ing the spatially informed MRI scan. Furthermore, the SBNN provides robust
probabilistic diagnosis that resembles clinical decision-making and accounts for
atypical, numerous, and early presentations of neurodegenerative disorders.
Keywords : Bayesian deep learning, neurodegenerative diseases, classification,





Neurodegenerative diseases are one of the most concerning group of diseases in
the clinical context since they are unpredictable and incurable (Dugger & Dick-
son, 2017). The World Health Organization (WHO) predicts that by 2040, as
many developed countries’ aging population keeps growing, neurodegenerative
diseases will become the second leading cause of death after cardiovascular disease
(Gammon, 2014). Neurodegenerative diseases, also known as neurodegenerative
disorders, comprise a heterogeneous group of chronic and irreversible conditions
characterized by the progressive degeneration of the structure and function of the
central nervous system (Mascalchi, 2005). These disorders attack the brain neur-
ons by causing abnormal functioning and degeneration which eventually leads to
their demise. Depending on the amount and severity of the neuronal damage,
common symptoms include movement disorders (ataxias) and cognitive impair-
ments (dementias). Thus, identifying and classifying neurodegenerative diseases
is not only crucial in clinical practice but also beneficial for developing appropriate
treatments and enriching clinical research.
One of the main tools to characterize neurodegenerative diseases is symptomat-
ology. Conventional diagnostic approaches are based on the clinical evaluation
of the symptoms; according to their range and frequency, a potential disease can
be inferred. However, studies have proved that symptoms reflect only partially
the functional changes in affected brain regions caused by the neural loss and the
changes in signal transduction and that they can be linked to multiple pathologies
(Dugger & Dickson, 2017). For instance, confusion and episodic memory impair-
ment are common manifestations in the early stages of Alzheimer’s, Parkinson’s
and Mild Cognitive Impairment. Likewise, in early disease phases or atypical
variants, the differential diagnosis between disorders only based on symptomato-
logy is inaccurate and unreliable (Chetelat & Baron, 2003; Gelfand, 2014; Morris
et al., 2001). Against this background, techniques to measure alterations in brain
physiology were proposed to support neurodegenerative disease classification.
An outstanding technique, magnetic resonance imaging (MRI), has transformed
the study of the human brain, and especially brain diseases since its inception in
1977. MRI is highly effective at identifying anatomical and structural changes in
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brain physiology by using the magnetic response of brain tissue molecules (Pool,
2002). Relatives changes in tissue water content indicate atrophy or degeneration
of brain structures, and usually, MRI is used to capture these changes. Measures
of abnormalities (also called biomarkers) derived from structural MRI have been
markedly useful regarding diagnosis and assessment of neurodegenerative diseases
(Stoessl, 2012). Clinical trials have exploited MRI potential in the characteriza-
tion of neurodegenerative chronic diseases such as Parkinson’s (Heim et al., 2017),
Alzheimer’s (Pantano et al., 1999) and Multiple Sclerosis (Filippi & Rocca, 2011)
and have established itself as a reliable tool for both the diagnostic process and
the monitoring of disease progression.
In MRI, neuronal damage caused by neurodegeneration is represented as at-
rophies or lesions whose intensities in MRIs differ from the surrounding, ap-
parently healthy tissue. A neurological specialist will study the images and will
quantitatively and qualitatively recognize the patterns. Both this information
and patient symptoms help to diagnose and assess the diseases. However, MRI
contributions are merely limited to visual inspection (Stoessl, 2012). An example
of this is the widely used McDonald criteria to identify Multiple Sclerosis. It
only considers the number of lesions (visible in MRI) and the number of clinical
attacks. Although MRI provides a straightforward way to recognize neurode-
generative disorders, spatial and temporal dissemination of the structural brain
alterations in early stages hinders disease characterization through human eye
checkup (Heim et al., 2017; A. J. Thompson et al., 2018).
1.2 Motivation
Due to the availability of MRI, there is an increasing interest to apply analytical
methods to provide insights into neurodegenerative disorders. Volumetric meas-
ures of regions of interest (ROI) (Fox et al., 2005; Lee et al., 2011; Serrano-Pozo
et al., 2011; Smeets et al., 2016; Tapiola et al., 2008), voxel-based morphometry
(Prinster et al., 2010; Schmitter et al., 2015) and comparison of cortical thick-
ness (Burton et al., 2004; Sailer et al., 2003; P. M. Thompson et al., 2001), have
explored MRI data to establish differential diagnostics. However, these methods
measure group differences and they are not extendable to individual diagnosis.
Another prominent approach is imaging feature extraction for classification and
prediction using deep learning. As opposed to the aforementioned methods, deep
learning is a prime approach for pattern recognition. Its potential in MRI lies in
feature extraction regardless of scale (Angermueller et al., 2016). Deep learning
techniques can extract distinctive features from voxel, vertex, and ROI levels.
Multiple deep learning studies have been successful in classifying and predict-
ing neurodegenerative diseases. Rabeh et al. (2016) and Kruthika et al. (2019)
successfully distinguish between normal controls and Alzheimer’s disease (AZ)
patients using supported vector machine (SVM), Aslani et al. (2019) employed
two-dimensional convolutional networks to classify MS patients into major clin-
ical stages. Another approach has focused on segmenting the brain changes and
relate them to a neurodegenerative disorder (Brosch et al., 2015; Chitradevi &
Prabha, 2020; Folle et al., 2019; Jain et al., 2015).
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These approaches have achieved high accuracy (over 93%) in binary and (over
79%) multi-class diseases classifications. Nonetheless, most of the studies focus
on distinguishing stages of a specific disease or discriminating healthy individuals
from patients. Studies of the classification of multiple neurodegenerative diseases
are scarce since this entails combining and standardizing diverse MRI sources.
Furthermore, accuracy results in deep learning methods such as SVM and convo-
lutional networks are partly suited for clinical prognosis since they cannot account
for uncertainty in diagnosis. Brain abnormalities that define neurodegenerative
diseases can be present before the onset of symptoms and more than one neuro-
degeneration process can be found in an individual (Dugger et al., 2014; Dugger
& Dickson, 2017). Methods that provide contingent outcomes are needed for
diagnosing patients in early stages or with numerous pathologies. Finally, spa-
tial heterogeneity of the changes in the brain metabolism is ignored. Since the
brain follows a spatial configuration, so does the neuronal loss that characterizes
neurodogerenerative processes. Regional damage obeys a distinct neurodegener-
ative process, that is, it occurs in specific regions depending on the underlying
condition. Xing et al. (2018) found that deep learning approaches for image
recognition display higher accuracies and prevent overfitting when spatial hetero-
geneity is introduced into the data. Overfitting describes features that arise from
noise or variance in the data, rather than its underlying distribution leading to
loss of accuracy. Meyer et al. (2018) proved that adding simple spatial compon-
ents such as geographic coordinates to machine learning techniques for spatial
interpolation can enhance both the stability and predictions of the model. In
MRI, Taschler et al. (2014) incorporated spatial locations of MS lesions to differ-
entiate between MS stages. Also, Illan et al. (2014) demonstrated that MRI data
coupled with cerebral spatial information - functional region labeling - increases
Alzheimer’s disease detection in early stages significantly.
These limitations are the main motivation for this research topic: the application
of deep learning techniques to MRI data to identify neurodegenerative disorders.
A particular focus of this work lies in the use of deep learning methods together
with Bayesian inference to supply probabilistic predictions. This study is focused
on the analysis of brain MRI scans and proposes a Bayesian neural network ap-
proach that uses spatially informed imaging data to diagnose Alzheimer’s, Par-
kinson’s, Multiple Sclerosis, and Mild cognitive impairment. Likewise, this thesis
indirectly attempts to enhance the potential use of MRI and to highlight the
importance of considering spatially informed data in MRI clinical analysis.
1.3 Related work
In the last 40 years, research on neurodegenerative diseases has blossomed as a
result of the introduction of neuroimaging techniques to automatically discover
disease biomarkers (Pool, 2002). One of the first researches on the detection of
neurodegenerative diseases through imaging data was published thirty years ago,
by de Leon et al. (1983). The study used Positron emission tomography (PET)
to detect physiological biomarkers in the brain tissues of normally aging subjects
and senile dementia patients. The conclusions of de Leon et al. (1983) formed
an important basis for further works and stimulated the inclusion of imaging
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techniques in the diagnosis of neurodegeneration disorders. In the upcoming
years, with the emergence of more sophisticated medical imaging modalities such
as MRI, disease detection and classification studies became prominent in major
medical journals.
Jack et al. (2003) compiled Alzheimer’s disease biomarkers based merely on MRI
data. Hotter et al. (2009) and Ge (2006) followed their example and identified
structural brain changes for Parkinson’s and Multiple Sclerosis. In each study,
a group of highly trained neurologists participated to support and ensure their
findings. Many studies made notable contributions in expanding neuroimaging
biomarkers for the diagnosis of neurodegenerative diseases: Frisoni et al. (2010)
in his research work attributed medial temporal lobe atrophy visible in MRI to
Alzheimer’s disease; Mahlknecht et al. (2010) found that found that atrophy in the
temporal, occipital and right frontal lobes is also evident in Parkinson’s patients,
however, volume and shape differ from the atrophic changes caused by AZ. Meijer
et al. (2017) established sound MRI criteria to separate Multiple Sclerosis from
Parkinson’s and Huntington Disease. Series of studies compiled and analyzed
MRI biomarkers to create reliable guidelines to expose neurodegenerative diseases
with overlapping symptomatology and atypical behaviors (Agosta et al., 2017;
Blamire, 2018; Martin-Macintosh et al., 2016a, 2016b).
Consequently, several semi-supervised techniques emerged in studies to support
diagnosis from unexperienced clinicians. Starting from volumetric measurements
of regions of interest (ROI), voxel-based morphometry, cortical thickness, and
principal component analysis (PCA) have been applied to classify neurodegener-
ative diseases. In this regard, Lee et al. (2011) highlighted the region of interest
approaches while conducting his research in identifying PD with 200 healthy in-
dividuals and PD patients. Similarly, Prinster et al. (2010) in their work on
identifying gray matter loss in MS patients mentioned how to classify the disease
following the different patterns of the brain lesions’ regional distribution. Tapiola
et al. (2008) distinguished between AZ and MCI by analyzing the volume and
spatial distribution of the cortical thickness.
In most of the cases, classification studies were limited to distinctions within
the same disorder. Development in MRI preprocessing suggested that many of
these methods should be capable of integrating multiple conditions Kuperman,
2004. Studies of more than one disease were gradually introduced. Research
was primarily focused on discriminating between neurodegeneration and other
pathologies like brain tumors (Kilic et al., 2013) and psychiatric disorders (Lin et
al., 2013). Subsequently, Burton et al. (2004) segregated AZ and PD considering
voxel-based morphometry in white matter. Similarly, Blazhenets et al. (2019)
used PCA to predict the development of AZ and to recognize dementia variations
such as MCI. These methods’ contributions grounded in brain imaging research
but were bounded by the modest number of patients and the inaccuracy of the
medical diagnosis.
In the last years, advances in machine learning and pattern recognition meth-
ods capable of handling high dimensional data have enabled the development of
new diagnostic tools derived from morphological analysis in MRI. From a clinical
point of view, the main challenge resides in recognizing signatures of a disease
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in the structural images that allow discriminating pathological from healthy sub-
jects. Since important features can be automatically learned by these techniques,
information extraction from MRI in advance is not necessary. Research work by
Díaz et al. (2010) and Sood and Khandnor (2019) have accentuated the poten-
tial of deep learning in learning characteristic hallmarks for disease designation.
Several deep learning approaches have been proposed to automatically classify
patients with neurodegenerative disorders. Magnin et al. (2009) used SVM to
characterize patients with AZ from elderly controls. Aslani et al. (2019), Karaca
et al. (2016), Khan et al. (2020) and Sweeney et al. (2014) developed convolu-
tional neural networks to separate normal control from AZ, PD, and MS. Other
approaches have targeted differential diagnosis within dementia (AZ and MCI)
(Rabeh et al., 2016) and MS types (Narayana et al., 2020).
In deep learning methods, measuring uncertainty associated with their predic-
tions is challenging (Valentin Jospin et al., 2020). This is particularly alarm-
ing in medical diagnostic applications, where silent failure can lead to dramatic
results. Tishby et al. (1989) proposed Bayesian inference to represent probabili-
ties in layered networks. In 1996, Neal (1996) in his doctoral thesis elaborated
on Bayesian learning and prediction uncertainties for complex neural networks.
Currently, Bayesian research in deep learning is infrequent and its application
in many fields remains unexplored. Consequently, few studies have been con-
ducted in medical imaging. McClure et al. (2018) performed brain segmentation
and measured its accuracy for quality control purposes. A novel method for
skull stripping in nonhuman primates using bayesian convolutional networks was
presented by Zhao et al. (2018). Both Herzog et al. (2020) and Khairnar (2020)
used Bayesian neural networks for detection of strokes and breast cancer respect-
ively.
Similarly, a few attempts of the inclusion of spatial information in neuroimaging
analysis, outside deep learning theory, have been conducted. Marschallinger et
al.’s (2017) research diagnosed MS fromMRI data with geostatistics by adding the
coordinates of the lesion. Taschler et al. (2014) modeled the spatial density of MS
lesions to distinguish MS stages using spatial point patterns. For AZ diagnosis,
Illan et al. (2014) subdivided the spatial components of the brain (regions) and
modeled their dependencies using a Bayesian network. All studies mentioned the
correlation between high diagnosis accuracy and spatial information derived from
the brain morphology.
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1.4 Aim and Objectives
This study aims to detect and classify neurodegenerative diseases using spatially
informed MRI data through deep learning models coupled with Bayesian infer-
ence. Additionally, the thesis indirectly seeks to enhance the potential use of
multiple MRI sources and to highlight the importance of considering spatially
informed data in MRI clinical analysis.
This study will attempt to answer the following questions:
• To what extent can the characterization of neurodegenerative diseases be
improved with the integration of spatial information in MRI data?
• How can uncertainty be included in deep learning models to represent prob-
abilistic predictions?
• How does spatially informed data improve the classification accuracy of a
deep learning model?
1.5 Outline
The thesis is organized as follows: Chapter 2 provides a theoretical background
of the medical and methodological concepts used in this thesis, which are all
related to MRI data analysis in neurodegenerative diseases. In Chapter 3, the
methodology of the proposed classifier is described in detail. Chapter 4 presents
the data on which the model is tested, and describes the experimental setup. In
Chapter 5, the results of the experiments are interpreted and discussed. Finally,




This chapter presents the background material relevant to the subsequent chapters
of the thesis. Section 2.1 covers the technical details of magnetic resonance ima-
ging, including image acquisition and processing methods. Section 2.2 provides
medical background on neurodegenerative diseases. Section 2.3 summarises the
methodology underlying the convolutional neural network models and methods
presented later in Chapter 3. Section 2.4 reviews some aspects of classification
including validation and, introduces a Bayesian approach for prediction uncer-
tainty.
2.1 Neuroimaging: Magnetic Resonance Imaging
Magnetic Resonance Imaging (MRI) has become an important noninvasive ima-
ging technique to produce three-dimensional images of the anatomy and physiolo-
gical processes of the body. MRI employs the body’s natural magnetic properties
to locate and map the amount of water in the tissues resulting in a detailed im-
age. MRI has found several applications in the field of medical science since it
provides a unique contrast between organic soft tissues and high spatial resolution
(Kuperman, 2004).
In magnetic resonance imaging (MRI) of the brain, structural MRI (sMRI) is used
to visualize details of the brain anatomy which are unchanging for short periods.
It has become a predominant tool to detect and represent abnormalities in the
physical appearance of the brain and to track changes over time. Structural MRI
is highly effective at identifying lesions and cerebral structural changes and there-
fore is widely used in the diagnosis and assessment of neurological diseases such
as Multiple Sclerosis, Alzheimer’s, Parkinson’s, and schizophrenia (Stoessl, 2012).
Although other modalities like Computed Tomography (CT), Positron Emission
Tomography (PET), and Electroencephalography (EEG) are also commonly used
in brain anatomy and brain activity imaging, they present poor spatial resolution
and, exempt for the EEG, dangerous exposure to ionizing radiations (Afaq et al.,
2017; Noachtar & Rémi, 2009). sMRI is considered the backbone for detecting
neurological disorders in the clinical context.
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2.1.1 Image acquisition
Magnetic resonance imaging relies on the nuclei spins of the hydrogen nuclei
present in high quantities in the body’s tissue. MRI forces the alignment of the
natural random nuclei spins’ orientation - a phenomenon known as resonance -
and its subsequent return to equilibrium - relaxation phenomenon - by using a
large pulsed external magnetic field. An MRI sequence is characterized by two
parameters. The Echo Time (TE) defines the time between the Radiofrequency
(RF) pulse and the signal measurement, and the Repetition Time (TR) repres-
ents the time between two RF pulses. When the TR between consecutive pulses
of the external magnetic field is short, a the T1-weighted imaging sequence is
produced. T1-weighted MRI uses the spins relaxation time after which the lon-
gitudinal component of the nuclear spins have fully returned to their equilibrium
orientation. In contrast, T2-weighted scans are obtained by using a long TE. T2-
weighted MRI employs the spin to spin relaxation time which is the time needed
for the transverse component of the signal to decay exponentially from its initial
value (Currie et al., 2013). Depending on the tissues, relaxation times vary. In
T1 modality, only fatty tissue exhibits bright responses given that the relaxation
time for water is about five times larger than for fat. Both fatty and water-based
tissue (mainly protons) are bright in the T2 modality (Stanisz et al., 2005).
Visualization of the affected and normal brain tissue only on T1 or T2 images
is far from optimal. The anatomical changes appear hypo-intense or normal
on T1-weighted MRI and are therefore hard to detect. A common standard
procedure for neurodegenerative diseases patients involves the use of a contrast
agent, usually Gadolinium, to enhance the contrast in the brain tissues (Xiao
et al., 2016). Gadolinium coupled with T1-weighted MRI improve the visibility
of lesions, inflammations, abnormal structure, and changes in the brain tissues.
2.1.2 Preprocessing
After the acquisition of an MRI scan, due to the nature of the data, it needs to be
processed before any statistical analysis, especially if the study involves multiple
sources, multiple scans, and/or multiple subjects. The collection of transforma-
tions from the data is called imaging preprocessing. There are numerous steps
in imaging preprocessing commonly used to reduce noise, adjust and standard-
ize the data. The steps’ order and relevance depend on the study aim and the
neurological criteria.
Basic prepossessing steps comprise image harmonization corrections to errors
derived from images acquired by multiple scans. Noise and underemphasized fea-
tures are amended using image contrast and inhomogeneity correction. Spatial
registration addresses errors that occur when scans from different subjects are
used and that stem from the different sizes and shapes of the brains. Errors oc-
curring due to head motion during the scanning can be corrected in that way, too.
It aligns the scans from each subject to a common brain template, usually, the
brain atlas templates provided by Montreal Neurological Institute (MNI). Addi-
tionally, intensity normalization is a recommended technique to standardize the
voxel intensities from every scan to be comparable among subjects and scanners.
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Preprocessing techniques allow comparing and analyzing brain MRI of different
diseases regardless of patient and scanner particularities.
2.2 Medical background: Neurodegenerative Di-
seases
In neuroanatomy, three main physiological components of the brain are distin-
guished: white matter (WM), gray matter (GM), and cerebrospinal fluid (CSF).
WM consists of myelinated axons that transmit electrical impulses between vari-
ous regions of the brain. GM contains mostly neuronal cell bodies and unmyelin-
ated neurons that are involved in brain functions like sensory and motor control.
The CSF derives from blood plasma and provides basic mechanical and immun-
ological protection to the brain (Mtui et al., 2016).
Neurodegenerative diseases comprise a variety of sporadic as well as inherited
conditions characterized by progressive loss and/or death of defined populations
of neurons (Mascalchi, 2005). Hallmark pathology of neurodegenerative diseases
is the damage of the neurons and their connections located in the GM and WM
tissue. Since neurons do not reproduce or replace themselves, their degenera-
tion results in incurable and debilitating conditions. The neurological damages
manifest in form of lesions, inflammations, and atrophy that can occur across the
brain and spinal cord (Gitler et al., 2017).
Neurodegenerative diseases can be broadly classified by their clinical present-
ations based on the anatomic vulnerable regions (brain areas of the affected
nerves) and their resulting clinical presentations such as movement disorders and
cognitive or behavioral disorders (Dugger & Dickson, 2017). Examples of neuro-
degenerative diseases are Alzheimer’s disease, Parkinson’s disease, and Multiple
Sclerosis. These diseases are diverse in their pathophysiology – with some causing
memory and cognitive impairments and others affecting motor and sensory func-
tions (Dickson, 2018; Duyckaerts et al., 2009; Gelfand, 2014). Depending on the
disease symptoms can include memory loss, muscle function loss, anxiety, cognit-
ive impairment, digestive and sexual dysfunction, mood disorders, and chronic
pain.
Currently, no neurodegenerative disease is curable. Most treatments available




Alzheimer’s Disease (AZ) is a specific neurodegenerative disease and is the most
common cause of dementia in old people contributing to 60-70% of cases. AZ
is one of the major causes of disability and dependency among elderly people
worldwide. AZ is characterized by reducing the hippocampal volume and cau-
sing progressive cerebral atrophy. The cause for AZ is not yet fully understood.
However, studies show that it is associated with the beta-amyloid deposits and
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neurofibrillary tangles in the cerebral cortex and subcortical gray matter, leading
to neuronal and synaptic loss (Wang et al., 2017). AZ clinical hallmarks include -
but are not limited - to loss of memory, spatial perception deficit, aphasia, apraxia
and personality and mood changes (Duyckaerts et al., 2009). AZ is inexorably
progressive and fatal within 5 to 10 years.
Parkinson’s Disease
Parkinson’s Disease (PD) is a common neurodegenerative disorder that causes
progressive damage in different regions of the brain. The pathologic feature that
correlates with signs and symptoms of PD is the neuronal loss in the substantia
nigra, more specifically, a portion of this nucleus called the pars compacta. Neu-
ronal degeneration in the substantia nigra leads to a reduction of dopamine levels.
This limits functionality in the regulation of major brain structures involved in
the control of movement. PD pathological processes manifest as multiple system
atrophy, progressive supranuclear palsy, and cerebrovascular affectations (Dick-
son, 2018). The triggering event in PD is unknown, but recent studies suggest
a role for loss of nuclear membrane integrity. PD’s main symptoms are bradyki-
nesia, postural instability, resting tremor, and rigidity. Other symptoms include
emotional disorders and cognitive deterioration (Antony et al., 2013).
Multiple Sclerosis
Multiple Sclerosis (MS) is one of the most concerning neurodegenerative diseases
in the clinical context since it is unpredictable and it affects not only the elder
population - as other chronic diseases like Alzheimer’s or Parkinson’s - but also
young adults (Cohen & Rae-Grant, 2012). MS is a chronic inflammatory and
demyelinating disease of the central nervous system that manifests as lesions in
affected regions of the brain and the spinal cord. MS lesions occur in the brain’s
white matter which connects neurons in the gray matter leading to limited neu-
ronal conductivity along neurons across the brain and between the brain and other
organs of the body. MS clinical manifestations are not exclusively neurological
(motor weakness, visual impairment, diplopia, dysarthria, ataxia, etc.). Recent
studies have shown that MS is also related to cognitive deficits such as attention
and concentration disorders, slow information processing, loss of memory, and
executive functions (Noseworthy et al., 2000).
Mild Cognitive Impairment
Mild cognitive impairment (MCI) is rapidly becoming one of the most common
clinical manifestations affecting the elderly population. MCI is the stage between
the expected cognitive decline of normal aging and the more serious decline of
dementia, Alzheimer’s disease (Morris et al., 2001). MCI generally reflects an
intermediate state that shares to a certain degree the pathological characteriz-
ation of AZ in vulnerable cortical regions including memory-related regions like
the hippocampus, and the visual association cortex (Riley et al., 2002; Schneider
et al., 2009). Symptomatology of MCI is strongly related to AZ clinical mani-
festations such as memory loss and language deficits. However, MCI usually does
not present mood and personality changes. Symptoms are not severe enough to
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significantly interfere with MCI patients’ daily life and usual activities.
2.2.2 Diagnosis
The diagnostic tool commonly used to assess neurodegenerative diseases is based
on the clinical evaluation of the symptoms. Also, traditional structural neuroima-
ging techniques, such as magnetic resonance imaging (MRI), help diagnose neuro-
degenerative diseases (Stoessl, 2012); their clinical usage provides promise in the
diagnosis and monitoring of disease progression. Other diagnostic methods com-
prise markers detectable in readily accessible tissues (blood or saliva) (Gelfand,
2014). Genetic markers are as well employed for diagnosing familiar forms of
neurodegenerative diseases and they include amyloid precursor protein in AZ,
gene mutations in α-synuclein protein in PD or IgG, and IgM antibodies in CSF
in MS (Dickson, 2018; Dugger & Dickson, 2017; Noseworthy et al., 2000). The
combination of multiple techniques seems to improve disease diagnosis.
The main classification for the diagnosis of AZ has been the National Institute of
Neurological and Communicative Disorders and Stroke and the Alzheimer’s Dis-
ease and Related Disorders Association (NINCDS–ADRDA) criteria (McKhann
et al., 1984). These criteria combine clinical and neuropathological patterns and
assign diagnoses based on the stage of symptoms. Since atrophy caused by AZ
seems to be an inevitable, inexorably progressive concomitant of neurodegenera-
tion, MRI-based measures of atrophy are regarded as valid markers of AZ state
and progression for several reasons (Chetelat & Baron, 2003). MCI is considered
an intermediate state between normal cognition and dementia, and therefore AZ
biomarkers also help to diagnose it.
In PD, clinical criteria are key; there is no definitive test for diagnosis. Genetic
mutations or variants, neuroimaging, and cardinal motor test features are poten-
tial biomarkers that improve diagnosis and allow the identification of persons at
risk (Jankovic, 2008). Symptomatology is generally considered the cardinal signs
of PD: PD is mainly diagnosed based on the symptoms. MRI helps to detect PD
due to the reduction of the size of nigral regions caused by the disease.
There are no markers specific for MS diagnosis. Diagnosis mainly depends on
medical history and neurological examination. MS is characterized by attacks
which are defined as new neurological deficits associated with an anatomical brain
localization that persist for more than 24 hours (Gelfand, 2014). MS patients
present attacks only visible in magnetic resonance imaging.
2.2.3 MRI criteria
Neuronal degeneration develops into anatomical changes visible in magnetic re-
sonance imaging. Although MRI is one of the main sources for the diagnosis
of neurodegenerative diseases, the correlation between physical brain abnormal-
ities and clinical symptoms is merely approximate. The reason for this are the
neural plasticity and regeneration mechanisms that atone damage (Horner &
Gage, 2000). MRI can help to detect a neurodegenerative disease, but it can not
associate brain-damaged regions to any specific disease symptom (Stoessl, 2012).
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MRI sequences show different aspects of each disease activity and therefore dif-
ferent MRI criteria are adopted. T1-weighted and T2-weighted scans are the most
common sequence to identify the damage caused by the diseases. T1-weighted
sequences display most of the biomarkers associated with AZ, PD, MS, and MCI.
T2-weighted scans are used to assess the overall disease burden. However, T2-
weighted sequences suffer from high visual variability in regions with atrophies
and/or inflammations. This can cause equivocal interpretations in neurodege-
nerative diseases MRI (Frisoni et al., 2010; Mangia et al., 2013; Sahraian et al.,
2010).
Table 2.1: Summary of biomarkers in T1-weighted sequences.
Disease Appearance on MRI Description in diagnostic criteria
AZ hypointense (dark) Atrophy in temporal lobes and medial
parietal cortex
PD hyperintense (bright) Atrophy in nigral regions
MS hyperintense (bright) Lesions across the brain and spinal cord
MCI hypointense (dark) Mild atrophy in temporal lobes and
medial parietal cortex
The presence of atrophy in the medial temporal lobes is an established and val-
idated biomarker for the diagnosis of AZ, PD, and MCI. The simplest way to
assess atrophy is by visual inspection of coronal T1-weighted MRI. T1-weighted
scans for PD highlight vascular, space-occupying or demyelinating lesions within
the basal ganglia or brainstem. In MS, T1-weighted sequences display chronic
or persistent hypo-intense lesions indicating permanent axonal loss and neuronal
damage.
Figure 2.1: MRI most common biomarkers for degenerative
patients and healthy controls.
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2.3 Methodological background: Deep Learning
Deep Learning (DL) is a sub-field of Machine Learning Research, introduced as
the intersection of research areas of neural networks, artificial intelligence, graph-
ical modeling, optimization, and pattern recognition. DL involves learning mul-
tiple levels of representation and abstraction that help to make sense of data such
as images, sound, and text (Arel et al., 2010). DL techniques are inspired by the
functioning of human brains and are based on the principle of parallel processing.
They consist of multiple layers or stages of nonlinear information processing and
methods for supervised or unsupervised learning of feature representation at suc-
cessively higher, more abstract layers (Deng & Yu, 2014). DL enables exploiting
complex labeled or unlabeled data to learn distributed and hierarchical feature
representations and to make effective predictions about them. Many DL networks
such as convolutional neural networks, deep neural networks, recurrent neural
networks and recursive neural networks have been successfully applied to diverse
fields including computer vision, natural language processing, medical image ana-
lysis. DL architectures have proven high recognition and classification accuracy
and have outperformed traditional machine learning and statistical techniques
(Schmidhuber, 2015).
2.3.1 Convolutional Neural Networks
A Convolutional Neural Network (CNN) is a special kind of neural network usu-
ally applied to analyzing visual imagery. CNNs are models inspired by biological
neural networks that replace dense matrix multiplications with convolutions and
filters in at least one layer. This allows representing the input data in hier-
archical structures (Schmidhuber, 2015). CNNs are specialized neural networks
that exploit data topologies, e.g., images as a grid of pixels. Due to its prop-
erties, CNN is arguably one of the most important current image classification
methods. Traditional neural networks are characterized by one-dimensional ar-
chitectures composed of Fully Connected (FC) layers, whereas CNN is composed
of convolutional layers where hidden activation is calculated by multiplying small
local inputs against weights, and spatially, local association is exploited by apply-
ing a local pattern of connectivity between adjacent neural layers (Lopez Pinaya
et al., 2019). The resulting weights are then shared across the entire input loca-
tions and generate a feature map as an output. Finally, the collection of outputs
of each convolutional layer is shared with the next layer. Sharing the output from
neuron to neuron allows high level feature extraction and uncovers hidden latent
relations in the data.
2.3.2 Architecture of a CNN
A CNN typically consists of a set of alternatively stacked layers that transform
input volumes into outputs using differentiable functions. A convolutional block
- also called convolutional layer - is composed by convolution, activation, and
pooling layers (Figure 2.2). A convolutional layer is followed by one or more fully
connected layers for high-level reasoning. Fully connected layers assign feed-
forwarded scores to the n-dimensional inputs. At last, a loss layer measures
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the deviation between the predicted and true labels. A detailed explanation is
presented below.
Figure 2.2: A CNN is viewed as a stack of convolutional
layers formed by convolution, activation and pooling layers.
Convolution
The convolution layer represents the core concept of a CNN: to consider the
spatial structure of the n-dimensional input. A convolution layer consists of
filters - namely kernels - which extract features learned by the network over the
images. A convolution layer produces different feature activation values at each
location in the image to generate a feature map as output (Deng & Yu, 2014).
From a mathematical point of view,
y(t) = (x ∗ w)(t) =
∫
x(τ)w(t− τ)dτ (2.1)
where t ∈ R, τ ∈ R, x : R → R, and w : R → R. The resulting function
y : R → R after applying the convolution operator, denoted with an asterisk , to
the functions x and w, is defined as the integral of the product of both functions
after one is reversed and shifted (τ). The function x is usually referred to as the
input and w is a weighting function known as kernel. The output y is named
feature map.
In a computer the inputs are discrete. The implementation of a convolution layer
in a discrete space can be written as




where t can only take integer values.
In practice, the input x and the kernel w are not functions but multidimensional
discrete arrays - also called tensors - of size n-dimension.
Finally, a discrete convolution can be redefined as a finite summation over tensor
elements. For instance, a 3D convolution is defined as
Y (i, j, k) = (X ∗W )(i, j, k) =
m∑ n∑ l∑
X(m,n, l)W (i−m, j − n, k − l) (2.3)
where Y , X, and W are three-dimensional tensors denoting the output feature
map, the input three-dimensional data and the kernel function respectively.
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Activation
The purpose of the activation layers is to introduce non-linearities into the net-
work to enable non-linear representations. Activation functions increase the non-
linear properties of the decision function learned by the network, without affecting
the output of the previous convolution layer. Activation layers are often placed
right after a convolution occurs, but many combinations are possible.
Figure 2.3: Activation functions: Sigmoid(a), Tanh (b),
and ReLU (c)
The most common activation functions are shown. in Figure 2.3. Sigmoid and
Tanh are similar functions, they squash the inputs into a non-linear space of
range [0,1] and [-1,1] respectively. However, they are not commonly used because
they saturate gradients and their outputs are zero-centered. In contrast, Recti-
fied Linear Unit (ReLU) is the most common activation function for CNNs. It
thresholds the negative inputs to zero (Csáji, 2001). ReLU has non-saturating
properties and low computationally cost.
Pooling
Pooling layers are used to simplify the feature maps produced by the previ-
ous convolution and activation layers. In pooling, predefined functions are ap-
plied to summarize the signal and spatially preserve discriminant information
(Schmidhuber, 2015). There are many pooling operations, the most common be-
ing the max pooling operation. Max pooling selects the maximum value of the
neurons for a specific region.
Other functions such as average pooling or L2-norm pooling are used as well.
These are characterized by extracting the average (or weighted average) value of
the neurons. A pooling layer parameter comprises the size of the window and
stride (number of steps between the consecutive convolutions).
Fully Connected
After a convolutional layer composed by convolution, activation, and pooling
operations extracts low-level features from the data, the high-level reasoning of
the network is interpreted by fully connected layers. A Fully Connected (FC)
layer takes the output of the previous layers, flattens them and turns them into
an n-dimensional vector where n is the number of classes or labels to classify. The
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Figure 2.4: 4 x 4 Max pooling operation
output produced by this layer is the probabilistic score that a feature belongs to
one of the classes. In a FC layer, neurons are connected to every neuron in the
previous layers. FC layers are analogous to the layers in a typical multilayer
perceptron (MLP) (Lopez Pinaya et al., 2019).
Classifier
The classifier layer calculates the output class probabilities for the input FC
layers. It computes the deviation between the true labels of the input and the
label predicted by the network (Deng & Yu, 2014). This is known as cross-
entropy loss. The most common classifier for multi-class classification is the
softmax function which transform the logits into probabilities.
The softmax is a normalized exponential function that transforms the k-dimensional
CNN output vector Y of values to another k-dimensional vector S(Y ) of values
in the range [0, 1] that add up to 1. S(Y ) represents a categorical probabilistic
distribution. The softmax function is defined as:





2.3.3 Training a CNN
The training of a CNN is the optimization process to find the set of weights
that minimize the differences between the predicted classes and the ground truth
classes, i.e, the actual classes of the data.
Loss
Loss is the function that minimizes the deviation between the predicted and the
real classes. The loss function determines the optimal set of parameters that
reduce model error (Lopez Pinaya et al., 2019). These parameters are known
as the weights and bias learned by the network. In multi-class classification
problems, the SoftMax loss is computed using the cross-entropy, a natural way
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to measure the difference between two probability vectors.
L(S(Y ), T ) = −
k∑
i=0
Ti log (Si) (2.5)
L is the loss function of a categorical probabilistic distribution S(Y ) and true class
labels T defined through the ground truth classes. The loss function denotes the
negative log-likelihood of the i given instances.
Regularization
One of the most important aspects of CNNs is how well they generalize to unseen
data. When the loss in the training set is much higher than the one in the test
set, the model is overfitting and thus achieving poor generalization.
CNNs are expressive models particularly prone to overfitting given their non-
linear hidden nature and a large number of parameters. In this context, a well-
defined CNN relies on the selection of architectures that maximize generalization
and the development of techniques to prevent overfitting. The process of avoiding
or preventing overfitting is called regularization and some of the most successful
techniques include L1 and L2 regularization and dropouts.
Dropout Dropout is the most applied technique to avoid overfitting in convo-
lutional neural networks. Dropout operations are usually performed after fully
connected layers (Srivastava et al., 2014). The concept is to randomly drop units
and connections between fully connected layers with a determined probability
(Figure 2.5). Dropout prevents units from co-adapting and reduces overfitting
significantly.
Figure 2.5: Dropout technique applied to a fully connected
network.
Optimization
Optimization algorithms exist to force fast convergence in the training process.
Gradient descent is an iterative optimization technique to minimize the loss by
updating the weights of neurons in every iteration through a backpropagation
mechanism. A CNN models a function that processes a training data set using
a set of weights for the network layers and computes the loss for that input.
This process is called the forwardpass. The loss is then used to compute the
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gradients, and the gradients are used to update the weights. This process is called
backwardpass.
Famous algorithms include the Stochastic Gradient Descent with momentum
(SGD) and the Adaptive Moment Estimation (Adam).
Stochastic Gradient Descent Stochastic Gradient Descent (SGD) is a spe-
cific case of gradient descent that estimates the loss and gradient by using a
mini-batch of n training samples per iteration (epochs). In SGD, a learning rate
α determines the step size in the direction of the gradient of the loss function.
SGD with momentum is computed by adding a fraction γ of the update vector
of the last step Mt1 to the current update vector.
Mt = γMt−1 + α ∇f (Wt, X, T ) (2.6)
Adam Adaptive Moment Estimation (Adam) proposed by Kingma and Ba
(2015) is a optimizer based on mini-batch gradient descent that computes adap-
tive learning rates for each parameter. It keeps both the exponentially decaying
average of past gradients M ′t and the past squared gradients Mt
M ′t = γ
′M ′t−1 + (1− γ′)∇f (Wt, X, T )
Mt = γMt−1 + (1− γ)∇f 2 (Wt, X, T )
(2.7)
where Mt is the momentum in iteration t, γ is a fraction of the update vector of
the last step Mt−1. ∇ the gradient and f(∗) the loss function depending on the
weights W , the training set X and the true labels T .








Finally, these biased corrected moment estimates are used to update parameters
using the Adam update rule:




where α represents the learning rate.
2.3.4 Bayesian Neural Networks
Bayesian neural networks (BNN) combine neural network and stochastic mo-dels
with the latter forming the core of this integration (Neal, 1996). Traditional
Neural Networks focus on representing data through arbitrary functions. In con-
trast, statistical models (also called probabilistic models) represent the data based
on direct specifications over the model parameters. BNN introduces stochastic
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components in a neural network to simulate multiple possible models with an as-
sociated probability distribution. This allows explicit uncertainty inference in the
underlying processes of the neural network (Valentin Jospin et al., 2020). BNN
can produce uncertainties on the predictions and draw the distributions of the
parameters learned by the model (Bishop, 1997).
Let θ denote the models which represent the weightsW and the biases b of a neural
network NN . Be p(θ) the probability distribution of all possible θ models. ε
represents the random noise derived from a NN being an approximation. The
more similar the models are, the lower is the uncertainty.
θ ∼ p(θ)
y = NNθ + ε
(2.10)
BNN is an stochastic artificial neural network trained using Bayesian inference
(MacKay, 1992).
Bayes’ Theorem
Bayes’ theorem describes the probability as a measure of belief in the occurrence
of events and states that the prior beliefs influence the posterior ones. The Bayes
theorem can be stated as
P (H | D) = P (D | H)P (H)
P (D)
(2.11)
where H is the hypothesis and D is data. P (D | H) is the likelihood, P (H) the
prior belief and P (D) the evidence. P (H | D) is considered the posterior belif.
A BNN understands the neural network architecture as a functional model y that
depends on data x and the stochastic model as the prior distribution over p(θ)
and prior confidence in the predictions of the model p(y | x,θ). p(θ) can be
considered to be the hypothesis H and the training set is the data D. Applying
independence between the model parameter and the inputs,
P (θ | D) = P (D | θ)P (θ)
P (D)
=




A marginal probability distribution that measures the uncertainty of the model
can be calculated once the Bayesian posterior is computed. The marginal prob-
ability distribution p(y | x,D) is indirectly sampled from equation 2.10. θ is
sampled from the variational distribution qΦ(θ) defined in the section below.
p(y | x, D) =
∫
θ
p (y | x,θ′) p (θ′ | D) dθ′ (2.13)
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BNN gives the relative probabilities of each class as an average prediction. This








In Bayesian inference, a model must be fed with prior information before it ob-
serves the data (Fan et al., 2008). In BNN setting prior distribution is a diffi-
cult task due to neural network’s complexity and a large number of parameters
(Bishop, 1997).
BNN assumes a prior distribution on the model parameters, e.g, a Gaussian prior
distribution over the model weights. Assuming a normal prior on the coefficient
of the network is known as a good practice in over-parametrized neural networks
(Kingma & Welling, 2014). According to the central limit theorem, regardless of
the true underlying distribution, samples taken from data will steadily approxi-
mate a normal distribution. Likewise, as the number of hidden units increases, the
prior over functions implied by such priors converges to a Gaussian process(Neal,
1996).
p(θ) = N (0, σI) (2.15)
Priors are closely related to deep learning regularization techniques (Valentin
Jospin et al., 2020). Optimizing model weights to minimize the loss function
through a regularization function is equivalent to finding the most likely weights
under a posterior distribution given a prior distribution.
Variational Inference
Variational inference is a method for learning an approximation of the posterior
distribution (Kingma & Welling, 2014). Variational inference is very popular in
BNN since it is a scalable method that performs particularly well in large neural
network architectures (Valentin Jospin et al., 2020).
Variational inference as opposed to its counterpart Markov Chain Monte Carlo
(Hoffman et al., 2013), is not an exact method. Instead of sampling from the exact
posterior distribution, a variational distribution qΦ(θ) parametrized by paramet-
ers Φ is defined. The neural network learns the values of Φ such that qΦ(θ)
resembles closely the exact posterior; Kullback-Leibler divergence can measure
this resemblance.
In terms of Φ, Kullback-Leibler divergence is defined as,












In order to compute DKL (qφ‖P ), P (θ | D) also has to be computed. To avoid











dθ′ = log(P (D))−DKL (qφ‖P ) (2.17)
MinimizingDKL (qφ‖P ) is equivalent to maximizing the ELBO given that log(P (D))
only depends on the prior. The ELBO, as any other loss function in CNN, can be
optimized applying stochastic gradient descent to variantional inference (Hoffman
et al., 2013).
Deep learning, as in statistics, constructs qΦ(θ) from sample conjugate distribu-
tions in the exponential family such as multivariate normal, betas and gammas
(Valentin Jospin et al., 2020).
2.4 Methodological background: Hidden Markov
Random Fields
A hidden Markov random field (HMRF) model is a particular case of hidden
Markov models (HMM). HMM are stochastic processes derived by a Markov
chain whose state sequence cannot be observed directly, only through a sequence
of observations. HMM are very convenient to model context-dependent entities
by characterizing their mutual influence through conditional Markov random field
(MRF) distributions (Held et al., 1997). In instances with spatial information (2D
and 3D images), HMM constrains this information using the entities (pixels or
voxels) of the neighboring context. This allows forming mutually exclusive classes
that depend on the spatial similarities of the entities (Zhang et al., 2001). Since
the HMRF is spatially dependent, it can encode both the spatial and statistical
properties of an instance.
In MRF, the set of spatial locations S are associated among them following a
neighborhood structure N = {Ni, i ∈ S}. The joint probability of a pair of
random fields (Xi, Yi) is defined as
P (yi, xi | xNi) = P (yi | xi)P (xi | xNi) (2.18)
where ∀i ∈ S, and Xi’s neighborhood configuration is XNi ∈ L, L = {1, 2, ...., l}
being a set of possible classes or labels.
The HMRF model is defined as the marginal probability distribution of Yi de-
pending on the random variable parameter θ and XNi ,
p (yi | xNi , θ) =
∑
`∈L




f (yi; θ`) p (` | xNi)
(2.19)
21
where = {θ`, ` ∈ L}.
Assuming a Gaussian emission distribution, the HMRF model can be re-written
as
p (yi | xNi , θ) =
∑
`∈L
g (yi; θ`) p (` | XNi) (2.20)
where θ` = (µ`, σ`)
T and











2.4.1 Spatial Brain Segmentation
The Hidden Markov Random Field (HMRF) has been widely adopted in image
segmentation due to its classification nature (Nie et al., 2009). In the brain
imaging context, HMRF models are used to segment 3D images of the brain
into different classes (usually tissue) whilst also correcting for spatial intensity
variations. It is a robust and reliable method insensible to noise with probabilistic
volume tissue segmentation.
The segmentation of an MRI using an HMRF model involves assigning to each
MRI voxel a class label value taken from the set of classes, typically WM, GM,
and CSF tissues. The voxels are indexed using a 3D rectangular lattice struc-
ture and each voxel is characterized by an intensity value. The labeling of each
voxel depends on the probability of that voxel’s intensity belonging to a spatial
neighborhood of similar voxel intensities.
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Chapter 3
Spatially Informed Bayesian Neural
Network
This chapter describes the methodology of the Spatially informed Bayesian Neural
Network (SBNN). It is built on the theory discussed in Chapter 2. This chapter is
structured as follows: In the first section, a general workflow to design, train, and
use the SBNN is explained. The second section presents the model’s input data
emphasizing the spatially informed input. The third section covers the neural
network architecture and stochastic model configuration, including the prior and
variational posterior family. The fourth discusses the output final predictions
based on the summary of the marginal distributions given the output posterior
distribution. The final section summarizes the software and tools to build the
SBNN model.
3.1 Model Design
The Spatially Informed Bayesian Neural Network aims to identify a possible
neurodegenerative disease of a suspected patient based on a MRI scan. The
models analyze the MRI data together with a spatially informed layer to classify
a patient MRI scan into one of the five classes: Healthy, AZ, MCI, PD, and MS.
The output classification is a potential disease with an associated probability and
prediction error. SBNN combines a convolutional neural network, a stochastic
variational model, and a spatially informed input to produce predictions.
Figure 3.1 displays the workflow to build the SBNN. First, preprocessed MRI
scans (xλ) are used to generate the spatially informed layers (xγ) using the HMRF
model. The resulting MRI exemplifies a brain segmented in ` mutually exclusive
classes. Both the preprocessed MRIs and the segmentation MRIs are split into
training, validation, and test datasets. The training dataset (D) is the input of
the SBNN model. Then a functional model (NN θ) is chosen, i.e., a convolutional
neural network (CNN). This thesis selected four predefined model architectures
and proposed a new one. The five models were tested to detect the architecture
that best represents and generalizes the MRI data and to evaluate the effect of the
spatially informed input. The next step is the choice of a stochastic model, that
is, the prior distribution over the CNN kernel and bias parameters p(θ) and the
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prior confidence in the model predictions p(y|x,θ). Also, a variational posterior
family qΦ(θ) is defined; as the prior follows a normal distribution and so does the
variational posterior. The CNN is then trained with the input training dataset
and the stochastic parameters. During the training, the KL-divergence function
adjusts the posterior based on the priors and the ELBO function is maximized
to learn the variational parameters (CNN weights and bias). The training and
inference output is a posterior distribution over the model coefficients p(θ|D)
that is then marginalized p(y|x, D) to get the distribution of possible predictions
for a particular MRI scan for each disease. The predictions are summarized to



























D = (x, y)
D = ((xλ, xγ), y)
x = (xλ, xγ)
Posterior
Figure 3.1: Design to train and use the spatially informed
Bayesian neural network.
3.2 Model Input
One of the main goals of the SBNN is to prove that the inclusion of an explicit
spatial input in a CNN model improves classification accuracy. Consequently, the
SBNN model is fed not only by standard data but also by a spatially informed
input. The standard data corresponds to the preprocessed MRI scans (see section
4.3) and the spatially informed data to the brain segmentation using the HMRF
model.
The brain segmentation MRI scans (xγ) are obtained by applying the HMRF
model to the preprocessed MRIs (xλ). Three classes ` = 3 corresponding to the
WM, GM, and CSF are defined to the HMRF model for segmenting the brain.
These structures are selected since their spatial distribution over the brain and
volumes are highly correlated to the brain damage caused by neurodegenerative
diseases (Gitler et al., 2017). The output MRI scans summarize implicitly the
neighborhood structures between the voxels intensities and evidence abnormal
changes in those structures. Figure 3.2 displays the coronal, transverse, and
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sagittal views of a healthy subject MRI scan and its corresponding segmentation.
It is evident how similar neighboring voxel intensities are being assigned to the
same class or classified with the same label.
Figure 3.2: (a) Original MRI scan from a healthy sub-
ject; (b) Segmentation image produced by the HMRF model.
White color denotes the white matter tissue, light gray the
gray matter tissue and dark gray the cerebrospinal fluid.
Both the preprocessed and segmented MRI scans are split into datasets to train,
validate, and test the SBNN. For training and validation purposes, each pair
of MRI scans (xλi, xγi) is accompanied by its corresponding true ground disease
(yi). In the case of the model testing, true classes y are only used to evaluate the
predicted classes ŷ of the test dataset. Data augmentation for the input x was
performed by rotating, translating, and flipping the MRI scans. However, it did
not affect the models’ performance and prediction.
3.3 Functional and Stochastic models
The functional model NN θ consists of a 3D CNN with two inputs and two
branches. The first branch is designed to extract high-level features from the pre-
processed MRI scans. The second branch extracts information from the spatially
informed MR images. Both branches have identical convolutional layer archi-
tectures to maximize the features detection and to guarantee output common
dimensions. A fusion layer combines the output semantic features of both CNN
branches which are passed on to a set of fully connected layers. The FC layers
and a SoftMax activation at the last layer are trained to assign a predefined class
to the input 3D images, i.e., to predict the neurodegenerative disease for each
patient. Figure 3.3 summarizes the NN θ architecture.
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Figure 3.3: Schematic description of the proposed func-
tional model architecture for neurodegenerative diseases pa-
tients prediction.
Five 3D CNN architectures are used for the functional model branches. These
architectures consist of several 3D convolutional layers (convolution, activation,
normalization, and pooling) with different parameters (filter, kernel, strides, etc).
This study selects four 3D CNN architectures based on related state-of-the-art
brain multi-class classifications and proposes a new one.
The first 3D CNN architecture uses three simple convolutional layers and two
Fully Connected (FC) layers to classify computed tomography (CT) brain scans
into healthy scans (H) and abnormal scans containing subarachnoid hemorrhage
(SAH), intraparenchymal hemorrhage (IPH), acute subdural hemorrhage (ASDH)
and brain polytrauma hemorrhage (BPH). The second architecture, proposed by
Payan and Montana (2015), consists of three convolutional layers and three FC
layers. This model differentiates between Alzheimer’s disease (AZ), Mild cognitive
impairment (MCI), and healthy (H) subjects. Mzoughi et al. (2020) proposes a
more complex CNN architecture to distinguish between low-grade (LG) and high-
grade (HG) gliomas: eight convolutional layers with three fully connected layers.
Another multi-class classification approach is suggested by Parmar et al. (2020).
In their study, they classify four Alzheimer’s disease stages using fMRI scans and
a set of five convolutional layers and three FC ones. Table 3.1 shows the details of
the used state-of-the-art 3D CNN architectures for brain imaging classification.
Further details of the models can be found in the studies mentioned.
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Table 3.1: State-of-the-art CNN-based methods for
neuroimaging multi-class classification.
Author Disease Classes MRI Testingscans Accuracy (%)
Ker et al. (2019) CT Brain H, SAH, IPH, 399 72.68Hemorrhages ASDH, BPH
Payan and Montana (2015) Alzheimer’s stages H, MCI, AZ 2,275 89.47
Mzoughi et al. (2020) Brain glioma HG, LC 284 87.2tumors
Parmar et al. (2020) Alzheimer’s stages H, AZ 120 93.10(fMRI) LMCI, EMCI
This study proposed architecture, inspired by the AlexNet CNN (Krizhevsky et
al., 2017), has four convolutional layer groups and three fully-connected layers.
The detailed configuration of the networks is shown in figure 3.4. The input to
the CNN is a 3D preprocessed/segmentation MRI scan with a 91x109x91 size.
The convolutional layers compute their outputs by applying the convolutional
operations (and a ReLU activation) with 3D filters of the size 3x3x3, 5x5x5,
7x7x7, 9x9x9. The results are followed by max-pooling of size 2 and 1x1x1, 2x2x2,
3x3x3, 4x4x4 strides. The last three layers in the CNN are fully connected. These
FC layers include the neurons connected to all outputs of their precedent layers.
The FC last layer with a softmax activation has 5 neurons, which represent the
probabilities of a patient to belong to one of the five classes (healthy, AZ, MCI,
PD, or MS).
Figure 3.4: Proposed CNN architecture for each model
branch feature extraction from 3D MRI scans.
Batch normalization layers are placed after each convolutional layer to increase
network stability. FC layers are followed by dropouts to regularize and account for
overfitting. A detailed architecture implementation is mentioned in the Appendix.
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The second step, after defining a functional model, is to build the stochastic one.
The stochastic model assumes that the convolution and FC layers kernels and bias
(θ) are drawn from distributions. Using Bayesian inference, the prior p(θ), sur-
rogate posterior qΦ(θ), and divergence for both the kernel and bias distributions
are specified.
As variational inference method, the reparameterization estimator proposed by
Kingma andWelling (2014) is used. This method performs a Monte Carlo approx-
imation of the distribution integrating over the kernel and bias. It also regularizes
these parameters by minimizing the Kullback-Leibler divergence up to a constant,
also known as the negative ELBO on the marginal likelihood.
The prior p(θ) and variational posterior qΦ(θ) are taken as Gaussian distributions
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(3.2)
The prior confidence in the model predictions p(y|x,θ) is computed using the
softmax function in the last FC layer.
3.4 Training and inference
The CNN is trained using variational inference. The bias’s and kernel’s prior and
variational posterior are defined as Gaussian distributed. The KL-Divergence is
weighted by the number of training samples (see section 4.4.1) and the ELBO
functions measure the loss of the model.
The training constructs the posterior p(θ|D), in other words, the kernel and bias
distributions (marginalized distributions) given the training data. Ideally, these
distributions should be Gaussian distributed around the most probable values of
the CNN parameters.
3.5 Prediction
For the prediction, the variational Monte Carlo inference is applied to each pair of
MRI scan in the testing dataset to get its corresponding probability distribution
p(y|x,D) depending on the output posterior p(θ|D) (CNN output weights). This
can be done by executing the SBNN n times (or iterations) for an input x.
A vector of relative probabilities (uncertainties) per disease is obtained by aver-
aging the n predictions (the mean value of the probability distribution) of the
SBNN. The final predicted disease ŷ is taken as the most likely disease, i.e., the
disease with the highest averaged probability.
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Chapter 4
Data and experimental design
This chapter describes the set of material employed in this work, in terms of
data and software. The chapter is structured as follows. Section 3.1 introduces
the characteristics of the MRI images and clinical data used in the experiment.
Section 3.2 explains the data retrieval process. Section 3.3 presents the set of tools
to standardize MRI coming from different sources. At last, Section 3.4 describes
the experimental design.
4.1 Data sources
This study employed 330 3D T1-weighted MRI scans from three different studies.
The first study corresponds to the Alzheimer’s Disease Neuroimaging Initiative*
(ADNI). The ADNI data set is part of a large multicenter study initiated in 2004
as a public-private partnership, led by Principal Investigator Michael W. Weiner,
MD. The primary goal of ADNI is to test whether serial magnetic resonance
imaging (MRI) and other biological markers and clinical and neuropsychological
assessment combined can measure the progression of mild cognitive impairment
(MCI) and early Alzheimer’s disease (AZ). The full study has over 10,000 MRIs
from 2294 cases and 500 control subjects. The data set available for this thesis
comprises a subset from the ADNI 3 cohort of the ADNI study. The subset
consists of 60 AZ, 30 MCI, and 75 Healthy (normal controls) subjects scanned
on a Siemens Prisma 3T scanner. 3D MPRAGE images were acquired since they
are considered the best in the quality ratings (Jack et al., 2008). The scans
were obtained with the following acquisition protocol: echo time 5 ms, time-to-
repetition 20.0 ms, flip angle 40, matrix size 256×256, slices 160, voxel dimensions
mm3). The subset also includes patient-specific covariates such as sex and age.
The second dataset was obtained from the Parkinson’s Progression Markers Initi-
ative (PPMI) study (Marek et al., 2011). The PPMI is a 5-year longitudinal study
*Data used in the preparation of this thesis were obtained from the Alzheimer’s Disease
Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within
the ADNI contributed to the design and implementation of ADNI and/or provided data but
did not participate in the analysis or writing of this report. A complete listing of ADNI invest-
igators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/
ADNI_Acknowledgement_List.pdf
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funded by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and
industry partners to identify biomarkers of PD progression. The PPMI counts
with brain imaging, clinical evaluation, and biospecimen collections for more than
2500 Parkinson’s disease patients and 1500 healthy controls subjects. The dataset
selected for this thesis is conformed by 60 PD patients and 75 Healthy subjects’
MRI scans and clinical data. The 135 T1-weighted scans were acquired following
the MPRAGE protocol with an echo time of 4 ms, 15.0 ms time-to-repetition, a
60 flip angle, matrix size of 256x256, 170 slices, and voxel dimensions of 1x1x1.2
mm3. The clinical data refers to the sex and age of the patients.
Table 4.1: Number of subjects and their mean age.
Disease Subjects Mean AgeFemale Male Total Female Male Total
AZ 25 35 60 72.8 76.2 74.8
MCI 10 20 30 60.5 70.5 65.1
PD 23 37 60 60.8 63.1 64.25
MS 23 7 30 40.8 34.1 39.2
Healthy 91 59 150 63.7 66.3 64.7
Total 172 158 330 62 67 64.5
In 2017, the University Medical Center Ljubljana (UMCL) disseminated a public
MS dataset of 30 MS patients including MR images and biological data. The
publicly available dataset was created to encourage further use and research in
MS lesions segmentation. A 3T Siemens Magnetom Trio MR system imaged
the cohort of 30 patients. 3D T1-weighted scans have the following specifica-
tions: echo time 20 ms, time-to-repetition 200.0 ms, flip angle 120, matrix size
of 408x512, 144 slices and voxel dimensions of 0.42x0.42x3.3 mm3. The study
conducted by the UMCL provided a novel protocol for creating reference white-
matter lesion segmentation based on multi-rater consensus. For more details see
Lesjak et al. (2018). This thesis uses the full dataset from 30 patients compris-
ing 3D T1-weighted scans and biological data such as sex and age of the study
participants.
Table 4.1 provides an overview of the main characteristics of the data set. The
average age is relatively similar across diseases. The largest discrepancy can be
observed for MS, which affects the young population. Subjects in this group on
average tend to be younger than subjects in groups of the other diseases.
4.2 Data retrieval
All 330 MRI scans were downloaded in the newer standard NIfTI format for brain
imaging processing. Patients’ sex and age variables from each study were merged
into a single data-set in CSV format.
For downloading data of the ADNI and PPMI studies, an access request was sent
to the Image Data Archive (IDA) center through its website (https://ida.
loni.usc.edu/). IDA is in charge of providing systems and resources to help
collect, manage, and share data from brain clinical trials and research studies.
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IDA granted access to the data from both studies within two to three weeks
after sending the request application. Data from the UMCL is publicly available
and was downloaded from the university’s laboratory of imaging technologies
(http://lit.fe.uni-lj.si/tools).
4.3 Data preprocessing
Preprocessing of the dataset involves numerous steps to clean and standardize
the raw data before its analysis. Preprocessing is a mainstay to increase the
sensitivity of analysis and to certify the validity of any model that involves MRI
scans.
Figure 4.1 shows a raw and preprocessed MRI scan from a healthy person. In
the processed MR image, the voxel intensities and locations were corrected. Also,
subjects and scanner specific effects were removed. The processed scan shares the
spatial architecture and dimensions of the Montreal Neurological Institute (MNI)
template brain atlas (91x192x91 2mm3). This noise-free MRI scan can be used
in further analysis, i.e. classification analysis.
Figure 4.1: (a) Original MRI scan from a healthy subject;
(b) Preprocessed MRI scan of the same healthy subject.
Classifying different neurodegenerative diseases requires accurate preprocessing
and careful feature learning due to the fact that similar changes can be caused by
different diseases. Preprocessing prevents ambiguous recognition during image
analysis and inequity in the voxels’ intensities. The preprocessing of MRI data
has a major influence on the high and consistent accuracy of MRI further analysis
(Parmar et al., 2020).
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In the sub-sections below, a detailed preprocessing workflow for this study dataset
is explained.
4.3.1 Inhomogeneity correction
Inhomogeneity intensity correction (also known as bias field correction) is a tech-
nique to adjust low frequency smooth undesirable signals that corrupts MRI im-
ages because of the inhomogeneities in the magnetic fields of the MRI scanners.
A bias field blurs images reducing their contents and changing the intensity voxel
values so the same tissue has different gray level distribution across the image
(Juntu et al., 2008). Inhomogeneity correction regulates voxels intensity values
based on a particular tissue and allows further analysis such as segmentation and
classification which assume spatial invariance of the MRI scans. For this thesis
dataset, an N4 (Improved N3 Bias Correction (Tustison et al., 2010)) was applied.
4.3.2 Brain extraction
Brain extraction removes non-brain tissue such as the skull and neck from an MRI
scan of the whole head. Since this project focuses on the brain tissue, non-brain
voxel areas are deleted from the MRI data. The brain extraction was performed
using the Fast Robust Automated Brain Extraction algorithm (BET) (Smith,
2002). As the raw MRI scans contain a lot of neck tissue (non-brain matter), the
centre-of-gravity is computed to find the brain true centre in order to improve
the brain tissue extraction.
4.3.3 Spatial Registration
Spatial registration refers to the process of aligning two images so that their
common features overlap and their differences are emphasized and readily visible
(Penny et al., 2007). Spatial registration performs spatial transformations to
one or multiple images to make locations (voxels) have a similar interpretation.
Specific voxels in particular locations can be only constrained in brains with
equivalent spatial domains.
During a MRI session, a particular high-resolution T1-weighting structural scan
is obtained according to the subject’s brain shape and layout and the particular
parameters of the scanner. To conduct a population-level analysis every image
must have the same conditions in resolution, size, and spatial distribution. This
type of registration is called registration to a template.
Since the data of this thesis come from different sources and patients, a non-
linear symmetric diffeomorphic image registration (Avants et al., 2008) method
was used to spatially transform the 330 T1-weighting scanner into a reference
template. Literature suggested the brain atlas of Montreal Neurological Insti-
tute (MNI) due to its high-spatial-resolution and unbiased properties. The MNI
template is a standard magnetic resonance imaging template brain volume for
normal population (Penny et al., 2007). This template defines a representative
brain of the population derived of averaging the dimensions, size and locations of
brain MRI’s from 152 healthy individuals.
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4.3.4 Intensity Normalization
MRI intensities are acquired in arbitrary units making them incomparable across
sites and between subjects. Even MRI scans acquired with the same protocol
can not be compared. This affects the performance, prediction, and inference of
further MRI analysis. Intensity normalization is a key step before performing
between-subject or between-time intensity comparisons at the voxel level. It
ensures comparability across images by bringing the intensities to a common
scale across patients (Penny et al., 2007).
The voxel intensity values of this thesis dataset were normalized using the Re-
moval of Artificial Voxel Effect by Linear regression (RAVEL) (Fortin et al.,
2016). The method removes present unwanted variation after a white stripe in-
tensity normalization, a robust method based on parameters obtained from a
sample of normal-appearing white matter. The RAVEL algorithm normalizes
the voxel intensity values by decomposing the variation of the intensities into a
biological component (clinical covariates) and technical variation (scan effects).
RAVEL algorithm used patients’ age and sex as clinical variables to produce the
normalized voxel intensities for each MRI in this study.
4.3.5 Image Harmonization
Differences in MRI scanners and acquisition protocols generate technical between-
scanner variations that hinder the detection of imaging features associated with
clinical covariates. Image normalization eliminates scanner effects and allows
comparisons of images across imaging sites and scanners. Like intensity normal-
ization, image harmonization algorithms model the biological variables and the
scanner effects to remove unwanted variation. However, image harmonization
methods include explicitly scanner parameters.
In this study, the ComBat image harmonization algorithm (Fortin et al., 2018)
was used to harmonize cortical thicknesses of the 330 MRI scans. ComBat proved
to be a powerful method to combine and study multi-source brain imaging data
while increasing the power and reproducibility of subsequent statistical analyses.
4.4 Experimental design
4.4.1 Dataset Splitting
To train, validate, and test the SBNN model, the 330 MRI scans were split using
the simple random sampling technique. It is an intuitive and efficient technique
to randomly assign observations to subset datasets. The images were randomly
shuffled and assigned to training, validation, or test dataset.
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Table 4.2: Number of MRI scans per training, validation
and test dataset.
Disease Training Validation Test
Percentage 70% 15.4% 14.6%
AZ 42 9 9
MCI 21 5 3
PD 42 9 9
MS 21 5 3
Healthy 105 23 22
Total 231 51 48
The training dataset, used by the SBNN model to learn each disease features,
consists of 231 (70%) T1-weighted preprocessed scans. The validation dataset
and test dataset are composed of 51 (15.4%) and 49 (14.6%) preprocessed images
respectively as shown in Table 4.2. The full dataset was split per disease to
guarantee the same distribution of each disease in each subset dataset.
4.4.2 Experimentation
The five CNNs are trained for a maximum of 100 iterations using the Adam
optimizer with an exponential decay function of initial rate δ = 1x10−5. The
batch size is set to a default value of 32 training samples. The input training and
validation sets are shuffled upon generation.
The 3D CNN with the highest accuracy over the test dataset (data that the
model never has seen) is chosen and transformed into a SBNN using variational
inference. The bias and kernel prior and variational posterior are defined as
Gaussian distributed. The mean µ and σ2 variance are initially set to 0 and
0.1 respectively. The KL-Divergence is weighted by 231, the number of training
samples.
The Monte Carlo number of iterations is set to n= 1000. Probability distributions
per disease are obtained for each of the 49 test samples. For one sample, the mean
value of every disease probabilities is chosen to obtain the predicted relative
probabilities. The disease with the highest relative probability is taken as the
final prediction.
4.4.3 Evaluation
The predicted disease is constrained with the ground truth one to generate an
evaluation metric. This metric is usually summarized by a Confusion Matrix
(Table 4.3 ) which consists of four possible combinations: True Positive (TP),
False Positive (FP), False Negative (FN), and True Negative (TN).
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Table 4.3: Confusion Matrix.
Actual Class
True False
Predicted Class True True Positive False NegativeFalse False Positive True Negative
A True statement refers to a correctly classified class (positive or negative), and a
False statement refers to an incorrect classified class (positive or negative). Based









F1 − Score =





TP + TN + FP + FN
(4.4)
Precision refers to the ratio of positive MRI scans correctly classified within the
correct class. Recall describes the portion of positive MRI scans correctly classi-
fied in all classes. F1-Score is the harmonic mean of precision and recall. Accuracy




This chapter presents and discusses the results of the experiment described in
Chapter 4. It is structured as follows. The first section shows the incidence of
the spatially informed layer on the models and a neural network model is chosen
as a functional model of the BNN. Section two presents a performance evaluation
of the SBNN and its parameters. Then, the third section focuses on the accuracies
of the predictions of the test data.
5.1 Spatially informed Input
The five CNN architectures were trained with the same parameters and the same
training, validation, and test datasets (see section 4.4.2). Table 5.1 shows the
accuracy results of the five networks with and without the spatially informed
input.
For the five architectures, without including the spatially informed input, the
training, validation, and test accuracy oscillate between 0.49 to 0.75%. The
architecture proposed by Mzoughi et al. (2020) performs particularly well in the
training and validation dataset but poorly in the test dataset; this means that the
CNN is overfitting, in other words, it is learning the data high-level features but
it is unable to generalize them to unseen data. Among the CNN architectures,
the lowest classification accuracy (49%) was obtained from the model of Ker
et al. (2019). This can be possibly explained by its simple architecture: three
convolutional layers and two FC layers. The few semantic features learned by
the network are not enough to classify or detect a specific class. The highest test
accuracy for this group corresponds to this thesis proposed architecture with a
value of 0.64%. Although it represents a relatively high value compared to other
architectures, it is considered a low value for classification purposes.
Differentially, the test accuracy for the five CNNs architectures with the spa-
tially informed input range from 0.68 to 0.83%. This study proposed architecture
outperforms the state-of-the-art model in terms of the validation (85%) and test
(83%) accuracies. The Mzoughi et al. (2020) architecture presents the second-
highest test accuracy among the five models; however, as it happened in the
architecture without the spatially informed input, it suffers from overfitting. The
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CNN configuration from Parmar et al. (2020) as well as the one from Payan and
Montana (2015) exhibit the lowest test accuracies of the group with the same
value of 68%. However, Payan and Montana (2015) architecture performs better
in the training and validation datasets.
Table 5.1: Training, validation and test accuracy for the four
state-of-the-art and the one proposed in this thesis with one
branch (only MRI scans) and two branches (MRI scans plus the
spatially informed MRI scans).
Accuracy
CNN Architecture Inputs Training Validation Test
Ker et al. (2019) MRI 0.62 0.66 0.49MRI, SiMRI 0.74 0.70 0.74
Payan and Montana (2015) MRI 0.54 0.56 0.60MRI, SiMRI 0.61 0.62 0.68
Mzoughi et al. (2020) MRI 0.92 0.72 0.61MRI, SiMRI 0.99 0.77 0.76
Parmar et al. (2020) MRI 0.75 0.56 0.56MRI, SiMRI 0.92 0.75 0.68
Proposed MRI 0.75 0.66 0.64MRI, SiMRI 0.96 0.85 0.83
MRI: Preprocessed MRI scans; SiMRI: Spatially informed MRI scans.
Taking the results into account, two conclusions can be drawn. First, Adding the
spatially informed input improves significantly the training, validation, and test
accuracy for all the architectures. Overall, the accuracies increased between 8%
and 25%.
Figure 5.1 displays output from the first convolutional layer of the proposed
architecture for a patient with AZ. This output, also called a feature map or
activation map contains the most important features identified by a convolutional
layer. For the MRI scan (a), the activation features are mainly located in the outer
parts of the front and parietal lobes. In other words, CNN is detecting scarce
features for characterizing AZ. On the other hand, for the spatially informed
MRI scans (b), the identified features are clustered around the brain ventricles
and emphasize cerebral atrophy. These regions are known biomarkers to detect
AZ through MRI (Frisoni et al., 2010). The combination of both inputs boots
the CNN feature detection for the diseases.
In summary, the CNNs with a spatially informed input (MRI scans with explicit
spatial relations) can locate more and better features associated with a neurode-
generative disease. The spatially informed input provides richer information to
the classifier and thus it can detect neurodegeneration hallmarks for a disease.
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Figure 5.1: (a) Sagittal, coronal and axial slices from the
feature map of the first convolutional layer for a AZ patient’s
MRI scan. (b) Spatially informed MRI scan.
Second, this work proposed CNN architecture achieves better accuracy results
than the state-of-the-art ones. In all cases, the proposed architecture excels in
correctly classifying most of the MRI scans unknown to the model. This means
that it understands and generalizes the most relevant features of the diseases of
this study. A detailed evaluation of the CNN is described in the next section.
5.2 Model evaluation
As mentioned in the section before, the proposed CNN architecture overperformed
the four state-of-the-art models. It learns key spatial features disease-wise and
can generalize them.
Initially, the model showed an overall (testing) accuracy of 83%: 83 out of 100
MRI scans will be classified correctly. When the stochastic model, i.e., the prior
and variational posterior over the parameters were incorporated in the CNN,
the accuracy decreased to 81%. A loss of 2% occurred by transitioning from the
functional model to the stochastic model. Although the CNN accuracy is reduced
by adding the stochastic model, this latter allows confidence in the predictions.
It is fair trade-off between accuracy and inclusion of uncertainty. As defined in
Chapter 3, the combination of the spatially informed CNN and the stochastic
model is called spatially informed Bayesian neural network (SBNN).
Since there are distributions associated with the model parameters, the accuracy
obtained after testing the SBNN is just one value of a distribution of possible
values (probability distribution). After evaluating the model with 1000 trials
(iterations) an average accuracy of 81.52% was achieved. Overall, an input MRI
scan will have an 81.52% probability of being classified with the correct disease.
Table 5.2 shows the accuracy evaluation for the entire model and for each class.
The SBNN evaluation was performed using the 48 MRI scans of the test dataset.
Precision, recall, and F1-scores for each disease were calculated based on the
averaged multi-class confusion matrix for the 1000 trials. Macro average and
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weighted average metrics are also provided to measure the model accuracy with
consideration to the imbalance in the number of samples per class.
As observed in table 5.2, the highest precisions with a perfect score of 1.00 were
obtained for the classification of the diseases MS and PD. This means that there
is a 100% probability of classifying correctly an MRI scan coming from one of
these two diseases. Healthy and AZ precisions are highly accurate with values
of 86% and 76% respectively. MCI presents the lowest precision (25%) of the
group; only one out of four MCI MRI scans was properly classified. Since MCI is
considered an early stage of AZ and usually a subtle transition between normally
aging old patients and AZ (Morris et al., 2001), MCI precision was expected.
Most of the MCI MRI scans were classified into AZ and healthy classes (see
confusion matrix in Appendix). Recall for the five diseases varies from 50% to
100%. In MS, the classification is perfect and so is the recall. In WM tissue,
MS biomarkers present the most distinctive features among neurodegenerative
diseases (Mascalchi, 2005). The lowest recall belongs to MCI. This means that if
a MRI scan of a MCI patient (Actual Positive) goes through the SBNN, it will
be predicted in another category (Predicted Negative) with a 50% probability. In
the case of a healthy individual, there is only a 14% (1-0.86) chance of a MRI scan
to be assigned to another disease. F1-score might be considered as an alternative
precision measure since there is an uneven class distribution in the test dataset.
In terms of the F1-score, most of the diseases perform well except for MCI. MS
exhibits a perfect score and both PD and Healthy scores are considerably high.
AZ F1-score is lower than their counterparts’ precision and recall due to the
wrong classification of MCI MRI scans into the category. The support column
shows the number of MRI scans classified per class regardless if they belong to
the correct class or not.
Table 5.2: Evaluation metrics for the SBNN model and the
studied classes.
Disease Precision Recall F1-score support
AZ 0.76 0.75 0.71 8
MCI 0.25 0.50 0.33 2
PD 1.00 0.75 0.86 12
MS 1.00 1.00 1.00 4
Healthy 0.86 0.86 0.86 22
Accuracy 0.81 48
Macro avg 0.77 0.77 0.75 48
Weighted avg 0.85 0.81 0.82 48
Macro average resumes the precision, recall, and F1-score for all diseases assum-
ing that the classes are balanced. Considering the unbalanced test dataset, the
weighted average better summarizes these metrics. The SBNN has a precision
of 85%, a recall of 81%, and an F1-score of 82%. These metrics are consistent
with the SBNN averaged accuracy and support the potential of the model for
classifying neurodegenerative diseases.
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Figure 5.2: (a) ROC curves per disease; (b) micro and
macro curves for SBNN.
Figure 5.2 illustrates the ROC (Receiver Operator Characteristic) curves for each
disease. The ROC curve shows the trade-off between the proportion of observa-
tions that were correctly predicted to be positive (true positive rate) and the
proportion of observations that are incorrectly predicted to be positive (false
positive rate). Classes whose curves are closer to the top-left corner indicate
better performance. Curves closer to the 45-degree diagonal of the ROC space
expose less accurate classes. AZ, PD, MS, and Healthy classes tend towards ideal
classifications. Contrarily, the SBNN exhibits less accurate MRI scan classifica-
tion for MCI patients. This suggests that MRI scans without distinctive features
- associated with other diseases - could be randomly assigned to the MCI class.
The micro and macro average ROC curves also highlight the high accurate clas-
sification performance of the SBNN.
5.3 Model predictions
The SBNN was executed 1000 times in a particular MRI scan to obtain the
probability distributions per disease. The mean and standard deviation values
were extracted from the probability distributions to represent class-wise the pre-
dicted probability and error (two times the standard deviation) associated with
it. The class with the highest probability is considered the predicted class for
that MRI scan. If the predicted class corresponds to the ground truth class,
the classification is correct. If the predicted class differs from the ground truth
class, the classification is incorrect. If the mean probability for every disease does
not exceed a threshold probability of 0.5 (the minimum acceptable probability),
the MRI scan is not assigned to any of the five classes, i.e., the classification is
uncertain.
This procedure was performed in the 48 MRI scans of the test dataset. Three
predictions for three different AZ MRI scans are presented in Figure 5.3. The
probability distributions are log-transformed to improve visualization; the closer
the values are to 1, the higher the probability is. The first MRI scan (a) was
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correctly classified; the mean probability is 0.83 and error 0.13. The mean prob-
abilities for the other diseases are very low and, in most cases, it tends to 0. There
is an 83% chance that the MRI scan belongs to an AZ patient. The second MRI
scan (b) is not classified into any disease even though AZ exhibits the highest
probability among the group. The mean probability (0.45) is not high enough
to decide to which class the MRI scan resides. In this case, other clinical assess-
ments such as symptomatology or cognition tests should be included to diagnose
a disease. Uncertain classification can inform about early disease stages, wrong
ground truth class, or diseases ignored in the model. The final analyzed MRI
scan (c) demonstrates an incorrect classification. Healthy is the most likely pre-
dicted class with a probability of 0.55 and an error of 0.26. Three main aspects
affect the erroneous classification: i) the mean probability surpassed the decision
threshold only by 0.5, ii) the error is half of the predicted probability, and iii)
the mean probability for AZ is 0.43. This scan could come from an AZ patient
in an early stage even though the evidence states it belongs to the healthy class.
Uncertainties give contextual information to decide over a disease or another. De-
pending on the predicted probabilities, their errors, and the level of uncertainty,
a clinician can decide whether to integrate or not more information to support a
diagnosis.
Figure 5.3: (a) AZ MRI scan correctly classified; (b) AZ
MRI scan not classified; (c) AZ MRI scan incorrectly classi-
fied.
Figure 5.4 displays the mean prediction and error bars for the test dataset and
Figure 5.5 shows the boxplots summarizing the mean prediction of the MRI scans
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per each disease. AZ probabilities vary from 0.68 to 0.80 approximately. The
maximum error (second MRI scan) is about 10% and the minimum error (ninth
scan) is 3% approximately. AZ expected probability is 76%, in other words, the
chance of an AZ MRI scan to be correctly assigned to the AZ class. For Healthy
MRI scans, the probabilities go from 0.85 up to 1.0. The error bars show that the
classification of some scans is less precise. The expected probability for healthy
scans is around 92%.
Figure 5.4: Predicted probabilitY errorbar plots of the test
dataset per disease.
The probability predictions for MCI are mainly concentrated between 0.3 and
0.5. Only one scan is correctly classified with 70% confidence and low error.
The expected MCI probability is 61%, however, this value is biased by the only
corrected classified MRI scan. MS presents the highest probabilities ranging
from 0.90 to 1.0. For most of the scans, the error does not exceed 2%. This class
presents the highest expected accuracy (95%). PD predictions oscillate between
0.8 and 0.9. The mean error for the class is approximately 4.5% and 8.3 out of
10 PD scans are expected to be classified accurately.
The dispersion and accuracy of the mean probabilities are linked to the level
of alikeness between the training and test data. Since the SBNN learned the
characteristic features of each disease, a MRI scan whose features disagree is a
potential cause for an error in the classification.
Figure 5.5: Predicted probabilities boxplot per disease.
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Table 5.3 introduces the 95% confidence intervals for each disease. A confidence
interval indicates a likely range of values that encompasses the expected value
with a certain probability. MCI probabilities are lower compared to other dis-
eases; this can be explained by the number of samples in the test data and by
the overlapping features it presents concerning other categories such as AZ and
Healthy. MS MRI range of probabilities is almost perfect which means the SBNN
can easily categorize it. PD and Healthy classification accuracy can arise to 90%,
a relatively high accuracy value considering the false positives coming from other
classes (see Table 5.2). AZ predictions are precise considering the short range of
its confidence interval.











This thesis presented a Bayesian convolutional network for the classification of
neurodegenerative disease - Alzheimer’s Disease, Mild Cognitive Impairment,
Parkinson’s Disease and Multiple Sclerosis - using magnetic resonance imaging
data. To improve accuracy, the model took advantage of spatially informed MRI
data (introduced as a regional brain segmentation) and used a Bayesian approach
in which the model predictions have associated an associated level of confidence.
The proposed model was tested with MRI scans from four neuronal degenerative
disorders and healthy controls. The results showed that a Bayesian 3D neural
network, informed only by MRI data, can produce accuracy that outperforms
state-of-the-art methods. However, they also highlighted the limited separability
of some of the diseases, especially in disorders with few samples.
The results show a substantial increment (up to 25%) in the classification accuracy
of 3D convolutional neural networks by incorporating a spatially informed MRI
scan. Such an increment is a direct consequence of enhancing the CNN feature
detection through brain spatial information. Including the explicit spatial scan
results in detailed differentiation and separability between diseases. Although the
segmentation MRI scan improves the distinction of neurodegeneration processes,
there is a limitation in this approach. In highly correlated diseases, such as
Alzheimer’s and Mild cognitive impairment, the captured spatial changes are
insufficient to separate surely these conditions.
An advantage of the Spatially informed Bayesian neural network model lies in
the fact that it accounts for uncertainty. The SBNN model formulation explicitly
allows for probabilistic estimation of the CNN parameters which are used in the
convolutional layers. Additionally, the Bayesian framework allows for inference on
the predictions by summarizing the posterior predictive probabilities. Concerning
the prediction of neurodegenerative disorder, the probabilistic formulation of the
SBNN model naturally accounts for aleatoric uncertainty (inherent random noise)
and epistemic uncertainty (ignored information), and therefore, better represents
the uncertainty in clinical diagnosis. SBNN predictions can not only detect the
most likely disease of a patient, but they can also inform about patients with
atypical variants, numerous pathologies, early disease stages, or diseases ignored
in this research.
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The overall classification accuracy of the SBNN model shows that approximately
8 out of 10 MRI scans are classified correctly. However, there is room for improve-
ment regarding individual disease accuracy. PD, MS HL accuracies surpassed the
overall accuracy, but MCI and AZ could not. MCI’s low accuracy is not surpris-
ing since many studies consider this condition as a stage of AZ. Most of the MCI
MRI scans were wrongly classified by the model into the AZ class.
It is worth noting that data preprocessing is instrumental in comparing and ana-
lyzing MRI data coming from diverse data sources. This study indirectly proposes
a data preprocessing pipeline to integrate MRI scans from neurodegenerative pa-
tients. Although preprocessing varies depending on the research purpose, most
brain imaging classification studies need to standardize and clean data to guar-
antee accurate predictions. The authors of this work believe that the proposed
preprocessing schema could be implemented in neuroimaging studies involving
numerous MRI data sources.
In conclusion, this research shows how detecting neurodegenerative disorders can
be improved, considering explicit spatial information in MRI data. One of the
benefits of the proposed model is the combination of multiple diseases and the
ability of generate contingent diagnosis.
In future studies concerned with the same problem, the prediction accuracy may
be improved by including exogenous variables, related to clinical assessments,
which account for uncaptured hallmarks of the diseases. For example, psycho-
logical and cognitive tests that describes the antecedent clinical history and be-
havioural aspects of the patient. Furthermore, larger datasets and original MRI
scan dimensions need to be included to provide richer information.
The findings of this study are expected to be of direct clinical interest for neur-
ologists, physicians, and medical researchers. In a comprehensive overview, the
most important contribution of this thesis is that it is one of the first works that
considers an explicit spatial input for diseases classification, and assists diagnosis
with uncertainties. Essentially, it introduces a reliable automatic tool, that can
provide a fast and accurate diagnosis, and support both the treatments and pro-
gnosis of neurodegenerative disorders.
6.1 Limitations and recommendations
Limited dataset size and class imbalance are some of the main limitations of this
study. Given the learning nature of deep learning methods, larger datasets result
in better performance. Neural networks with small data sets cannot capture all
the heterogeneity representations of a disease, leading to less accurate predictions.
On the other hand, MRI image acquisition processes are usually complex and
expensive. Dataset sizes are bounded and restricted by specific study needs; in
many cases, for privacy considerations, MRI-related studies data is confidential
and only accessible to participating researchers and organizations. More publicly
available MRI data is necessary to exploit the potential of data-driven methods as
deep learning, and to develop robust classifiers insusceptible to other pathologies
and disease variations.
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Similarly, MRI data size and dimension are key features of computational require-
ments for deep learning algorithms. A MRI scan is a higher-dimensional image
data composed of millions of voxels. Processing hundreds of MRI scan present
challenges associated with memory and computation consumption when using
CNNs. For instance, MRI scans considered in this study were down-sampled to
a reasonable size (from 182x218x182 to 91x109x91) to be processed by the BNN.
Some studies have proved that covariates influence differential diagnosis classifiers
(Narayana et al., 2020; Taschler et al., 2014). Having clinical and biological
information from patients besides age and sex is needed to improve classification
accuracies. Further covariates are omitted in most studies to anonymize patients
and protect their identities.
6.2 Future Work
The use of automated techniques using brain imaging data is a promising area
of medical research, especially in the field of neurology. In a clinical context, the
development of methods that aid decision-making is decisive for the assessment,
treatment, and prognosis of neurodegeneration processes such as Alzheimer’s,
Parkinson’s, and Multiple Sclerosis. The methods presented in this thesis can
serve as a basis for including spatial information in neuroimaging analysis. The
use of spatially informed data offers an opportunity to enhance the detection
of neurodegenerative disorders. Additionally, the spatially informed input is not
only limited to neurodegenerative diseases. Given its nature, it can be extendable
to other brain conditions such as tumors, gliomas, and strokes, in which brain
damage is also spatially located.
A direct extension that could be considered is the addition of other spatial inform-
ation, for example, relative coordinates of voxels, distances between brain regions,
and voxel intensity densities. These alternative ways to encode spatial informa-
tion could enrich disease detection and account for subtle differences between the
voxel intensities from two similar disorders (like AZ and MCI).
The SBNN model considers four neurodegenerative disorders and healthy sub-
jects. In future work, the model can be extended by adding more degenerative
affections (Huntintung’s disease, Amyotrophic Lateral Sclerosis) and introducing
stratification within each disease (disease stages or types ). This latter could be
useful for early diagnosis and monitoring of the disease progression.
Another approach unexplored by this work but plentiful in clinical practice is the
inclusion of other MRI modalities. Although in most of the cases T1-weighted
scans display neurodegeneration biomarkers, other modalities such as T2-weighted
and FLAIR scans can be used to support the findings of the former. In a more
robust model, other modalities could be added to account for disease features
that are undetectable in the T1-weighted sequence.
An enhancement of this study concerning some diseases’ low accuracy and the
problem of miss classified MRI scans would be the integration of clinical and
biological information about patients. Currently, the only criterion for the SBNN
to detect a patient’s neurodegenerative condition is MRI data. However, clinical
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trials suggest that MRI-based information together with information derived from





This appendix provides some predictions of the SBNN model that were generated
after evaluating the 48 MRI scans of the test dataset. This information includes
the prediction estimate, error variance, most likely disease, and classification
status (correct, uncertain, incorrect). For those predictions that were uncertain,
only the prediction estimate is provided. The predictions correspond to MRI






The accuracy classification of the functional models improved after including the
explicit spatial MRI scan. This appendix includes the activation maps of the
first convolutional network for the architecture proposed in this thesis with and
without the spatially informed input. The feature maps were computed for each
neurodegenerative disease and healthy controls. The activation maps enhance
the CNN feature recognition (Biomarkers) associated with each disorder.
B.1 Alzheimer’s Disease
For the MRI scan (a), the activation features are located in the outer parts of the
front and parietal lobes, which are not characteristic features of AZ. Contrarily,
the spatially informed MRI scans (b) identifies features around the brain vent-
ricles and emphasize the medial temporal lobe atrophy ; this is a known biomarker
for the prediction of AZ. Likewise, high activation features occur in the entorhinal
cortex and hippocampal regions.
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B.2 Parkinson’s Disease
The activation features produced by excluding the spatially informed scan (a)
suggest that PD can be detected in the outer parts of the brain tissue. This is
erroneous. The feature maps including the spatially informed MRI scan (b) are
distributed all over the brain lobes. However, regions where the substantia nigra
is located are highlighted. The sign of nigral degeneration is a known biomarker
of PD.
B.3 Mild Cognitive Impairment
The MRI scan is locating features in the outer parts of the front and parietal
lobes, which are not characteristic features of MCI. The spatially informed MRI
scans are also erroneously detecting features outside the lobes. However, some
soft activation regions are located near to the entorhinal cortex and hippocampus.
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B.4 Multiple Sclerosis
For multiple sclerosis it is evident how the spatially informed input of feature
maps improves the recognition of the white matter lesions caused by the disease.
Likewise, the activation map emphasizes the corpus callosum. One manifestation
of MS is the slimming of this structure.
B.5 Healthy
For both the preprocessed (a) and spatially informed (b) MRI scan from the
healthy subject, most of the activation features are located in the outer parts
of the brain lobes. Also, some weak activations can be seen around the brain




A visualization format that produces insight into the behavior of the SBNN is
the confusion matrix. The confusion matrix represents the validation results after
performing 1000 trials for the test dataset. Correct, uncertain, and incorrect
classified scans were assigned to the most likely disease.
It can be observed that there is confusion between MRI scans from AZ and MCI
patients. Besides, some PD MRI scans get misclassified in AZ, MCI, and HL
classes. Another notable fact is that MS shows a perfect classification with 4 out






All the R code used in this thesis is bundled in
the NeuroNorm package (Payares, 2021). The
source code, including documentation for each func-
tion, can be found on GitHub, through the fol-
lowing link: https://github.com/DavidPayares/
neuronorm. The package, as many neuroimaging
tools, only works on Linux OS. The package is
optimized for images of neurodegenerative diseases
such as Alzheimer’s Disease, Mild Cognitive Impair-
ment, Parkinson’s Disease and Multiple Sclerosis,
but can easily be adapted to other pathologies.
The NeuroNorm package can be installed from git-
hub with the following code. The devtools package
should be installed in advance.
devtools::install_github("DavidPayares/neuronorm")
A reproducible preprocessing can be performed using the sample data in the
package. Example scripts can be found at https://github.com/DavidPayares/
neuronorm/blob/main/inst/example.R.
## ----------------------- Data Loading --------------------------
# Get general folder
folder <- system.file("extdata", package = "neuronorm")
# Get covariates
covariates <- system.file("covariates.txt", package = "neuronorm")
# Read covariates information
clinical_info <- read.csv(file = covariates, sep = ’;’)
## ----------------------- Preprocessing --------------------------
require(’neuronorm’)
# Preprocess MRI scans
paths_preprocess_patients <- preprocess_patients(folder, clinical_info)
# Outputs paths of the preprocessed MRI scans.
55
paths_preprocess_patients
## ----------------------- Image Visualization --------------------------
require(’oro.nifti’)




The python code used in this thesis for implementing the SBNN can be found at
https://github.com/DavidPayares/SBNN. The SBNN python scripts comprise
data loading, model training, model testing and predictions.
# Neurodegenerative Diseases Classification
# 3D Spatially Informed Bayesian CNN.
from tensorflow.keras.layers import Input, MaxPooling3D, AveragePooling3D, Flatten, BatchNormalization, Dropout,
Concatenate
from tensorflow.keras.optimizers import Adam, schedules
from tensorflow.keras.callbacks import ModelCheckpoint
from tensorflow.keras.models import Model
import tensorflow as tf









"""Spatially Informed Bayesian Neural Network.
Please see link−of−thesis for more information.
Parameters:
−−−−−−−−−−−
model_name: string, select one bayesian model among
"reparametrization", "flipout−kl" and "flipout−prior".
default model "reparametrization".
input_shape: list or tuple of four ints, the shape of the input data.
(91, 109, 91, 1) by default.
pooling: string, pooling methods. "max" for max pooling,
"avg" for average pooling. Default is "max".
drop_rate: float, dropout rate, default is 0.5.
training_data_length : int, numer of samples in the training data.






ValueError if model is not an allowable value.
"""







# Set bayesian model parameters
### Gaussian priors




# Layers weights and bias distribution posteriors
self.kernel_posterior = tfp.layers.default_mean_field_normal_fn(is_singular = False)
self.bias_posterior = tfp.layers.default_mean_field_normal_fn(is_singular = False)
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### Kullback−Leibler divergence
self.divergence_fn = lambda q,p,_: tfp.distributions.kl_divergence(q,p)/ self.training_data_length
# Build SBNN models
if model_name in {’reparametrization’, ’flipout−kl’, ’flipout−prior’}:
self.model = self.bayesianModel(self.input_shape)
else:
raise ValueError("Unknown model name. Allowed models are ’reparametrization’, ’flipout−kl’ and ’flipout−
prior’")
return
def conv3D(self, inputs, filter_size, strides):
"""Build a 3D bayesian convolution layer .
Parameters:
−−−−−−−−−−−
inputs: input tensor, it should be the original input,
or the output from a previous layer.
filter_size: int, the number of filters.




Tensor for convolutional layer.
"""
# Decide convolutional layer architecture based on selected model
if self.model_name == ’reparametrization’:























def dense3D(self, inputs, units, activation = ’relu’):
"""Build a 3D bayesian convolution layer .
Parameters:
−−−−−−−−−−−
inputs: input tensor, it should be the original input,
or the output from a previous layer.
units: int, Integer or Long, dimensionality of the output space.
Returns
−−−−−−−
Tensor for convolutional layer.
"""
# Decide convolutional layer architecture based on selected model
if self.model_name == ’reparametrization’:








elif self.model_name == ’flipout−prior’:
dense_layer = tfp.layers.DenseFlipout(units= units,
activation= activation,
kernel_prior_fn= self.kernel_prior)(inputs)
elif self.model_name == ’flipout−kl’:





def covLayer(self, inputs, filter_size, conv_strides, pool_strides):
"""Build a convolutional layer.
Parameters:
−−−−−−−−−−−
inputs: input tensor, it should be the original input,
or the output from a previous layer.
Returns
−−−−−−−
Tensor for convolutional layer.
"""
# Decide type of pooling (max or avg)
if self.pooling == "max":
pool = MaxPooling3D
elif self.pooling == "avg":
pool = AveragePooling3D
# Define the convolutional layer block
conv_layer = self.conv3D(inputs, filter_size, conv_strides)




"""Build the bayesian convolutional network.
Parameters:
−−−−−−−−−−−
inputs: input tensor, it should be the original input.
Returns
−−−−−−−
model: Keras Model instance, SBNN model.
"""
#### Intensities Branch (preprocessed MRI scans)
## Input layer
input_int = Input(shape= self.input_shape)
# Convolutional Layers
conv_int = self.covLayer(input_int, (3,3,3), (1,1,1), (1,1,1))
conv_int = self.covLayer(conv_int, (5,5,5), (1,1,1), (2,2,2))
conv_int = self.covLayer(conv_int, (7,7,7), (1,1,1), (3,3,3))
conv_int = self.covLayer(conv_int, (9,9,9), (1,1,1), (4,4,4))
# Fully Connected Layers
conv_int = Flatten()(conv_int)
conv_int = self.dense3D(conv_int, units = 512)
conv_int = Dropout(self.drop_rate)(conv_int)
conv_int = self.dense3D(conv_int, units = 128)
conv_int = Dropout(self.drop_rate)(conv_int)
#### Spatially Informed Branch (Segmented MRI scans)
## Input layers
input_si = Input(shape= self.input_shape)
# Convolutional Layers
conv_si = self.covLayer(input_si, (3,3,3), (1,1,1), (1,1,1))
conv_si = self.covLayer(conv_si, (5,5,5), (1,1,1), (2,2,2))
conv_si = self.covLayer(conv_si, (7,7,7), (1,1,1), (3,3,3))
conv_si = self.covLayer(conv_si, (9,9,9), (1,1,1), (4,4,4))
# Fully Connected Layer
conv_si = Flatten()(conv_si)
conv_si = self.dense3D(conv_si, units = 512)
conv_si = Dropout(self.drop_rate)(conv_si)
conv_si = self.dense3D(conv_si, units = 128)
conv_si = Dropout(self.drop_rate)(conv_si)
# Fusion layer
concat = Concatenate(axis = −1)([conv_int, conv_si])
concat = self.dense3D(concat, units = 512)
concat = Dropout(self.drop_rate)(concat)
# Classification Layer
if self.model_name == ’reparametrization’:




outputs = self.dense3D(concat, units = self.classes, activation = ’softmax’)
# Model definition
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model = Model(inputs = [input_int, input_si], outputs = outputs)
## Output Model
return model
#### Get the SBNN model
if __name__ == "__main__":
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